First‐line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis

First‐line chemotherapy for advanced/metastatic human epidermal growth factor receptor 2 (HER2)‐negative gastric/gastroesophageal junction cancer (GC/GEJC) has poor median overall survival (OS; <1 year). We report efficacy and safety results from Chinese patients in the phase III global CheckMate...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Tianshu, Bai, Yuxian, Lin, Xiaoyan, Li, Wei, Wang, Jufeng, Zhang, Xiaochun, Pan, Hongming, Bai, Chunmei, Bai, Li, Cheng, Ying, Zhang, Jingdong, Zhong, Haijun, Ba, Yi, Hu, Wenwei, Xu, Ruihua, Guo, Weijian, Qin, Shukui, Yang, Nong, Lu, Jianwei, Shitara, Kohei, Lei, Ming, Li, Mingshun, Bao, Nicole, Chen, Tian, Shen, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092493/
https://www.ncbi.nlm.nih.gov/pubmed/36121651
http://dx.doi.org/10.1002/ijc.34296

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092493/
https://www.ncbi.nlm.nih.gov/pubmed/36121651
http://dx.doi.org/10.1002/ijc.34296

Ejemplares similares